October 22, 2018
STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment
News
STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug ... Read more
October 19, 2018
Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma
News
The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its ... Read more
October 17, 2018
Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals
News
Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data ... Read more
October 15, 2018
FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia
News
The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual ... Read more
October 12, 2018
Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma
News
A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will ... Read more
October 10, 2018
Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma
News
The U.S. Food and Drug Administration has approved a combination of once-weekly Kyprolis (carfilzomib), developed by Amgen, and dexamethasone for the ... Read more
October 8, 2018
Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma
News
Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells ... Read more
October 3, 2018
EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma
News
The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for ... Read more
September 28, 2018
Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients
News
Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach ... Read more
September 26, 2018
Patient Power, Winship Cancer Institute Partnered for Myeloma Town Hall Meeting
News
In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for ... Read more
September 24, 2018
Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma
News
SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the ... Read more
September 19, 2018
Leukogene Therapeutics Awarded $2M to Advance Compound for Treatment-resistant Multiple Myeloma
News
Leukogene Therapeutics, a startup company from the Medical University of South Carolina (MUSC), has been awarded a $2 million ... Read more

$Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma$
$EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma$

October 22, 2018

STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment

News

STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). “There is a growing need for new treatment ... Read more

October 19, 2018

Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as a treatment for multiple myeloma patients ... Read more

October 17, 2018

Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals

News

Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience Survey reveals. The figure is much ... Read more

October 15, 2018

FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia

News

The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the small number of cancer cells that ... Read more

October 12, 2018

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

News

A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in patients with relapsed or refractory multiple myeloma. ... Read more

$Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma$

October 10, 2018

Once-weekly Kyprolis with Dexamethasone Approved in US for Relapsed or Refractory Multiple Myeloma

News

The U.S. Food and Drug Administration has approved a combination of once-weekly Kyprolis (carfilzomib), developed by Amgen, and dexamethasone for the treatment of multiple myeloma patients who failed prior therapies. “In ... Read more

October 8, 2018

Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma

News

Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the CD38 molecule as a potential treatment for multiple myeloma. ... Read more

$EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma$

October 3, 2018

EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma

News

The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of adults with multiple myeloma. Validation confirms that the ... Read more

September 28, 2018

Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients

News

Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach for heavily-treated multiple myeloma patients who have exhausted all approved ... Read more

September 26, 2018

Patient Power, Winship Cancer Institute Partnered for Myeloma Town Hall Meeting

News

In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for them, Patient Power and Emory Winship Cancer Institute partnered to host ... Read more